Impact of a Community Pharmacist-Delivered Information Program on the Follow-up of Type-2 Diabetic Patients: A Cluster Randomized Controlled Study.


Journal

Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864

Informations de publication

Date de publication:
06 2019
Historique:
received: 13 03 2019
pubmed: 3 5 2019
medline: 1 5 2020
entrez: 4 5 2019
Statut: ppublish

Résumé

Low-quality communication between patients and care providers and limited patient knowledge of the disease and the therapy are important factors associated with poor glycemic control in patients with type 2 diabetes. We conducted a multicenter study to determine whether structured and tailored information delivered by pharmacists to type 2 diabetic patients could improve patient treatment adherence, hemoglobin A1c (HbA1c) levels and knowledge about diabetes. One hundred seventy-four pharmacies were randomized to deliver an educational program on diet, drug treatment, disease and complications during three 30-min interviews over a 6-month period, or to provide no intervention, to type 2 diabetic patients treated with oral antidiabetic agents. Medication adherence was assessed by measuring the medication possession ratio and diabetes control by collecting HbA1c values. Levels of patient treatment self-management and disease knowledge were assessed using self-questionnaires. Three hundred seventy-seven patients were analyzed. The medication possession ratio, already very high at baseline in the intervention (94.8%) and control (92.3%) groups, did not vary significantly after 6 months with no difference between the two groups. Significant decreases in HbA1c were observed in both groups at 6 months (p < 0.001) and 12 months (p < 0.01), with significantly greater changes from baseline in the intervention group than in the control group at 6 months (- 0.5% vs. - 0.2%, p = 0.0047) and 12 months (- 0.6% vs. - 0.2%, p = 0.0057). Patients in the intervention group showed greater improvement in their ability to self-manage treatment (+ 4.86 vs. + 1.58, p = 0.0014) and in the extent of their knowledge about diabetes (+ 0.6 vs. + 0.2, p < 0.01) at 6 months versus baseline compared with the control group. Tailored information provided by the pharmacist to patients with type 2 diabetes did not significantly improve the already high adherence rates, but was associated with a significant decrease in HbA1c and an improvement of patient knowledge about diabetes. ISRCTN33776525. MSD France.

Identifiants

pubmed: 31049873
doi: 10.1007/s12325-019-00957-y
pii: 10.1007/s12325-019-00957-y
pmc: PMC6824455
doi:

Substances chimiques

Hypoglycemic Agents 0

Banques de données

ISRCTN
['ISRCTN33776525']
figshare
['10.6084/m9.figshare.7964879']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Pagination

1291-1303

Références

AIDS Patient Care STDS. 2014 Dec;28(12):622-7
pubmed: 25396706
Endocr Pract. 2016 Jan;22(1):84-113
pubmed: 26731084
Patient Prefer Adherence. 2016 Aug 16;10:1573-81
pubmed: 27574406
JAMA. 2006 Dec 6;296(21):2563-71
pubmed: 17101639
Behav Res Ther. 2004 Apr;42(4):409-22
pubmed: 14998735
J Manag Care Spec Pharm. 2016 May;22(5):493-515
pubmed: 27123912
Eur J Health Econ. 2018 Mar;19(2):189-201
pubmed: 28190188
Diabetes Care. 2017 Nov;40(11):1425-1432
pubmed: 28801473
Am J Manag Care. 2012 Apr;18(3 Suppl):S43-8
pubmed: 22558941
Saudi Pharm J. 2016 Jan;24(1):40-8
pubmed: 26903767
Diabetes Metab. 2013 May;39(3):250-7
pubmed: 23523643
Ann Pharmacother. 2004 Sep;38(9):1357-62
pubmed: 15238621
Patient Educ Couns. 2016 Jun;99(6):926-43
pubmed: 26658704
JAMA Dermatol. 2014 Aug;150(8):813-4
pubmed: 24898730
J Clin Pharm Ther. 2011 Oct;36(5):602-13
pubmed: 21143256
Clin Endocrinol (Oxf). 2014 Jan;80(1):47-56
pubmed: 23194193
BMC Health Serv Res. 2014 Nov 13;14:533
pubmed: 25391694
Diabetes Care. 2009 Jan;32(1):19-24
pubmed: 18852334
Ann Pharmacother. 2011 Feb;45(2):145-53
pubmed: 21304027
Diabetes Obes Metab. 2018 Jan;20(1):185-194
pubmed: 28730750
Chronic Illn. 2014 Dec;10(4):291-302
pubmed: 24567193
Curr Med Res Opin. 2014 Jul;30(7):1309-16
pubmed: 24502771
Diabetes Care. 2011 Jan;34(1):20-6
pubmed: 20929988
Pharmacoepidemiol Drug Saf. 2004 Sep;13(9):591-8
pubmed: 15362081
N Engl J Med. 2013 Jul 18;369(3):287-8
pubmed: 23863067
Diabetes Educ. 2011 Nov-Dec;37(6):801-12
pubmed: 22021025
J Diabetes. 2016 Jan;8(1):76-85
pubmed: 25565383
J Gen Intern Med. 2003 Aug;18(8):624-33
pubmed: 12911644
Am J Ther. 2014 Jul-Aug;21(4):234-9
pubmed: 23344108
J Cardiovasc Pharmacol Ther. 2012 Mar;17(1):57-64
pubmed: 21335480
Diabetes Care. 2018 May;41(5):929-932
pubmed: 29678864
Health Educ Behav. 2010 Dec;37(6):849-62
pubmed: 21076128
Pharm World Sci. 2006 Apr;28(2):65-72
pubmed: 16791717
Swiss Med Wkly. 2002 Jul 13;132(27-28):379-85
pubmed: 12428192
Expert Opin Pharmacother. 2017 Apr;18(5):503-515
pubmed: 28276972
Diabetes Care. 2017 Nov;40(11):1469-1478
pubmed: 28801475
J Manag Care Spec Pharm. 2017 May;23(5):573-582
pubmed: 28448779
Diabetes Metab. 2003 Feb;29(1):79-81
pubmed: 12629452

Auteurs

Yves Michiels (Y)

Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.
Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.

Olivier Bugnon (O)

Community Pharmacy, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Lausanne, Switzerland.
Community Pharmacy, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.

Annie Chicoye (A)

Institut d'Études Politiques de Paris, Paris, France.

Sylvie Dejager (S)

MSD France, Courbevoie, France.

Christine Moisan (C)

Department of Diabetology, Pitie Salpetrière, Paris, France.

François-André Allaert (FA)

Evaluation Chair BSB-Cenbiotech, Dijon, France.

Catherine Hunault (C)

MSD France, Courbevoie, France.

Laura Romengas (L)

Observia Group, Paris, France.

Hubert Méchin (H)

Observia Group, Paris, France.

Bruno Vergès (B)

Department of Endocrinology, Diabetology and Metabolic Diseases, CHU Dijon, Dijon, France. bruno.verges@chu-dijon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH